Valiant Laboratories

Valiant Laboratories

92.80
+0.78
(0.85%)
Market Cap
504.02 Cr
EPS
-0.51
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
127.98
52 Week Low
69.84
PB Ratio
1.58
Debt to Equity
0.41
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,725.10
#1 4,13,909.28
36.33
#1 54,729.00
12.06
#1 10,980
-18.99
64.93
6,611.00
1,75,501.28
80.63
9,712.00
0.89
2,191
23.05
46.65
3,695.30
1,25,065.74
62.55
11,539.40
6.99
1,911
19.91
74.11
1,541.20
1,24,483.93
23.36
28,409.50
7.12
5,291
9.88
65.36
1,275.10
1,06,416.16
#1 18.97
33,741.20
16.73
5,725
1.26
55.19
2,573.20
1,06,203.36
61.21
12,744.20
19.57
2,007
-10.91
55.92
970.60
97,665.07
21.54
23,511.00
13.82
4,615
-0.19
61.25
1,926.70
87,991.52
27.91
22,909.50
#1 19.94
3,306
#1 112.49
58.19
35,065.00
74,510.68
52.85
6,684.70
10.80
1,414
27.83
60.78
1,154.00
67,024.51
19.45
31,378.10
17.55
3,366
-0.50
55.87

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
-43.42 %
Net Income Growth
-98.97 %
Cash Flow Change
-96.63 %
ROE
-99.55 %
ROCE
-100.93 %
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Jun 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
84
72
92
54
63
42
33
22
25
37
56
Expenses
79
61
81
48
61
47
35
21
28
35
54
EBITDA
4
11
10
6
2
-5
-2
0
-3
2
2
Operating Profit %
5 %
14 %
10 %
7 %
-2 %
-16 %
-15 %
-13 %
-31 %
2 %
7 %
Depreciation
0
0
0
1
1
1
1
1
1
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
4
10
10
6
1
-5
-3
-0
-4
2
1
Tax
1
3
2
2
0
-2
-1
0
1
-1
0
Net Profit
3
8
8
4
1
-4
-1
-1
-5
2
1
EPS in ₹
1.65
4.70
2.41
1.31
0.24
-0.81
-0.33
-0.13
-1.09
0.54
0.16

Balance Sheet

Balance Sheet
2023
2024
2025
Total Assets
213
343
401
Fixed Assets
48
50
204
Current Assets
151
226
193
Capital Work in Progress
1
43
156
Investments
34
38
4
Other Assets
130
212
0
Total Liabilities
213
343
401
Current Liabilities
51
29
60
Non Current Liabilities
62
77
107
Total Equity
101
237
234
Reserve & Surplus
68
193
191
Share Capital
33
44
44

Cash Flow

Cash Flow
2023
2024
Net Cash Flow
-0
11
Investing Activities
-55
-144
Operating Activities
56
2
Financing Activities
-1
152

Share Holding

% Holding
Sept 2023
Oct 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
74.94 %
74.94 %
74.94 %
74.94 %
74.94 %
74.94 %
74.94 %
74.94 %
74.94 %
FIIs
0.00 %
0.00 %
0.00 %
3.48 %
1.89 %
0.00 %
0.00 %
0.64 %
0.63 %
DIIs
3.89 %
0.04 %
0.02 %
0.03 %
0.00 %
0.00 %
0.00 %
0.00 %
0.46 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
12.49 %
12.49 %
13.36 %
15.16 %
16.09 %
17.30 %
17.55 %
16.28 %
17.05 %
Others
8.68 %
12.53 %
11.68 %
6.39 %
7.07 %
7.76 %
7.51 %
8.13 %
6.92 %
No of Share Holders
37,434
37,434
15,821
14,914
14,249
15,189
15,692
15,036
14,432

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
19 Jul 2025 RIGHTS Rights
1:4
18 Jul 2025 104.70 103.20
20 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
20 May 2025 100.98 104.48
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Feb 2025 93.23 99.27
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 109.94 105.99
08 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2024 132.40 114.95

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Submission Of Letter Of Offer For Rights Issue Of Fully Paid-Up Equity Shares Of Valiant Laboratories LimitedJul 17, 2025
Intimation Of ISIN For Right Entitlements For The Purpose Of Right IssueJul 16, 2025
Rights Issue Of Equity Shares - Record Date July 19 2025Jul 15, 2025
Corporate Action-Outcome of Right issueJul 15, 2025
Announcement under Regulation 30 (LODR)-Raising of FundsJul 15, 2025
Board Meeting Outcome for Approval Of Terms Of Rights Issue Of Equity SharesJul 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Draft Letter Of Offer For Proposed Rights Issue Of Equity Shares Jul 10, 2025
Contact Details Of Key Managerial Personnel Of The Company Authorized Under Regulation 30(5) Of The SEBI (LODR) Regulations 2015Jul 09, 2025
Appointment of Company Secretary and Compliance OfficerJul 09, 2025
Announcement under Regulation 30 (LODR)-Raising of FundsJul 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On July 09 2025Jul 09, 2025
Board Meeting Intimation for Intimation Of Board Meeting For Fund RaisingJul 05, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJun 26, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMay 20, 2025
Financial Results For The Quarter And Year Ended March 31 2025May 20, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Dated May 20 2025.May 20, 2025
Board Meeting Intimation for Board Meeting Intimation For Considering And Approving Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2025.May 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Integrated Filing (Financial)Feb 07, 2025
Authorised Persons For Determining / Disclosing Material Events / Information.Feb 07, 2025
Financial Results For The Quarter Ended December 31 2024.Feb 07, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Dated February 07 2025.Feb 07, 2025
Board Meeting Intimation for Considering And Approving Audited Standalone And Consolidated Financial Results For The Quarter Ended December 31 2024.Jan 31, 2025
Integrated Filing (Governance)Jan 13, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 20, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 19, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2024
Statement Of Deviation For The Quarter Ended September 30, 2024Nov 13, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 13, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 12, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorNov 12, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 12, 2024
Financial Results For The Quarter Ended September 30, 2024Nov 12, 2024
Board Meeting Outcome for Outcome Of The Board MeetingNov 12, 2024
Board Meeting Intimation for Considering And Approving Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.Nov 07, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 14, 2024
Announcement Under Regulation 30 Of SEBI (LODR), 2015Oct 04, 2024
Closure of Trading WindowSep 26, 2024
Announcement under Regulation 30 (LODR)-Credit RatingAug 23, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 15, 2024
Statement Of Deviation & VariationAug 14, 2024

Technical Indicators

RSI(14)
Neutral
39.64
ATR(14)
Volatile
4.84
STOCH(9,6)
Oversold
13.21
STOCH RSI(14)
Oversold
7.50
MACD(12,26)
Bearish
-1.71
ADX(14)
Weak Trend
15.44
UO(9)
Bearish
39.72
ROC(12)
Downtrend And Accelerating
-12.01
WillR(14)
Oversold
-80.95